The loss of Novo Nordisk (Wegovy) weight and diabetes (OZEMPIC) is no longer in the short term, American architects said on February 21, 2025, a decision that is expected to reduce access to affordable copies of popular medicines.
STEVE CHRISTE/CORBIS/GETTY PICTURES